Cytogent

Why resistant cancer

Resistance is where cancer care is decided.

Targeted therapies have changed cancer care, but for many patients with advanced disease the cancer eventually adapts and stops responding. What happens in the weeks after that moment, the next test, the next treatment, the next trial, shapes the rest of the patient’s journey.

Three gaps we close

Detection. Knowledge. Access.

  • Gap 1

    The detection gap

    Signs of resistance are spread across scans, reports and lab results. Cytogent brings them together and flags them early.

  • Gap 2

    The knowledge gap

    New treatments and studies appear faster than any team can read. Cytogent brings the relevant insight to each patient’s case.

  • Gap 3

    The access gap

    Willing patients and open studies often never meet. Cytogent connects them.

Quality of care

How better resistance care improves quality of care.

  • Earlier testing after progression
  • Better-prepared tumour-board decisions
  • More patients offered a study
  • Less time lost between lines of treatment
  • Better data for the next generation of therapies

Why now

Three things have changed.

  • AI can read real records

    AI can finally read real clinical records, not just structured fields.

  • Europe is opening health data

    Europe is opening secure health-data access through the European Health Data Space.

  • Pipelines follow progression

    Drug pipelines are increasingly focused on patients who progressed on earlier therapies.

Questions

Quick answers.

What is resistant cancer?

Cancer that stops responding to a treatment that worked before. Doctors also call it treatment resistance or acquired resistance.

Why does the moment of resistance matter so much?

What happens in the weeks after it, the next test, the next treatment or the next trial, shapes the rest of the patient's journey.

Which cancers does Cytogent support?

Cytogent is built for resistant solid tumours, including cancers treated with targeted therapies.

Does Cytogent diagnose resistance?

No. It helps the care team see signs earlier, prepare for decisions and find options. The clinician decides.

Resistance is where care is decided. Be part of the network.

We are onboarding a founding group of cancer centres and research partners in Europe.